Neurocrine Biosciences is a biopharmaceutical company that discovers, develops, and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders. The company generates revenue primarily through its marketed FDA-approved products—INGREZZA for tardive dyskinesia and Huntington's disease chorea, and CRENESSITY for congenital adrenal hyperplasia—which it sells through a specialty sales force and specialty pharmacy channels in the U.S. and select international markets. Neurocrine supports its commercial portfolio with a diverse pipeline of mid- to late-stage candidates across multiple therapeutic areas and drug modalities, targeting the goal of launching approximately one new medicine every two years.